In March 2025, the National Institute of Allergy and Infectious Diseases (NIAID) began soliciting comments on the future of the four Division of AIDS (DAIDS)-sponsored HIV clinical research networks: ACTG, IMPAACT, HPTN, and HVTN.
A global coalition reacted to two deals announced today to make long acting lenacapavir (LEN-LA), a 6 monthly HIV PrEP (pre-exposure prophylaxis) injection that provides virtually 100% protection against HIV infection, at $40 per person per year in 2027.
A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry.
On September 16 at 11 am (U.S.) savesaidsresearch.org starts a massive marathon to save AIDS funding.
TAG and the Community Research Advisors Group (CRAG) are happy to introduce the TB Representative Studies Rubric (TB RSR), a new tool that community advisory boards (CABs) can use when designing and reviewing clinical trials protocols. The TB RSR is a 17-item questionnaire that assesses whether TB treatment trials include the types of people who get TB.
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
Save the Date: Monday, October 20, 2025 , when our Research in Action Awards return this fall! We'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV). Get your tickets now!
This Hepatitis C virus (HCV) storyboard describes the experience of Sibusiso Dlamini in Tsawne, South Africa. Sibusiso is a young man who began using substances for leisure in high school, and later in life switched to injecting substances for a stronger high.
The World Health Organization (WHO) guidelines for diagnosing TB have evolved along with available technologies and tools that are increasingly accurate, simple, and efficient at detecting TB and resistance to a wider range of TB drugs.